Copyright Seeking Alpha
QuidelOrtho narrows 2025 revenue guidance to $2.68B–$2.74B as margin initiatives deliver $140M in cost savings Nov. 06, 2025 5:46 AM ETQuidelOrtho Corporation (QDEL) StockAI-Generated Earnings Calls Insights Comments Earnings Call Insights: QuidelOrtho Corporation (QDEL) Q3 2025 Management View CEO Brian Blaser highlighted "another solid performance that reflects the strength of our diversified global diagnostics portfolio," reporting organic sales growth of 5% excluding COVID sales and the U.S. donor screening business. He pointed to "significant Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Quick Insights Through cost savings, restructuring, and margin expansion initiatives with adjusted EBITDA margin increasing to 25%, plus ongoing efforts in procurement and manufacturing efficiencies. 2025 revenue is guided at $2.68-$2.74B, EBITDA at $585-$605M, margin target at 22%, and adjusted EPS at $2-$2.15. Guidance ranges narrowed, but midpoints were unchanged. Risks include tariff impacts, ERP system conversion with negative temporary cash flow, ongoing exit from U.S. donor screening, LEX Diagnostics margin dilution, and goodwill impairment from stock price decline. Recommended For You More Trending News
